Eledon Pharmaceuticals
ELDN
49 hedge funds and large institutions have $69.4M invested in Eledon Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 9 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
2% less funds holding
Funds holding: 50 → 49 (-1)
16% less capital invested
Capital invested by funds: $82.2M → $69.4M (-$12.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$6.69M |
| 2 |
Bank of New York Mellon
New York
|
+$4.88M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$783K |
| 4 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
+$445K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$393K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$6.88M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.05M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$613K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$346K |
| 5 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$203K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCP
51
Tourbillon Capital Partners
New York
| – | -$6.88M | -3,191 | Closed |
|
|
52
AllianceBernstein
Nashville,
Tennessee
| – | -$613K | -285 | Closed |
|
|
DCM
53
Discovery Capital Management
South Norwalk,
Connecticut
| – | -$203K | -94 | Closed |
|
|
SO
54
STRS Ohio
Columbus,
Ohio
| – | -$39.1K | -19 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$6.18K | -3 | Closed |
|
56
Invesco
Atlanta,
Georgia
| – | -$5K | -2 | Closed |
|
|
JG
57
Jefferies Group
New York
| – | -$5K | -2 | Closed |
|
58
Barclays
London,
United Kingdom
| – | -$2.06K | -1 | Closed |
|
ELDN Hedge Fund Activity: Q3 2015 in Review
49 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2015, worth a combined $69.4M — down 16% from $82.2M a quarter earlier.
Fund positioning in ELDN was balanced in Q3 2015: 9 funds opened new positions, 9 closed out, 20 added to existing stakes and 7 trimmed.
The largest buyer was Sabby Management, adding an estimated $6.69M. The largest seller was Tourbillon Capital Partners, exiting entirely with an estimated $6.88M sold.
- 49 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2015, down from 50 in Q2 2015.
- Funds reported $69.4M of Eledon Pharmaceuticals stock for Q3 2015, down 16% quarter-over-quarter.
- 9 funds opened new Eledon Pharmaceuticals positions in Q3 2015 and 9 closed out, a net change of 0 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2015 was Sabby Management, an estimated $6.69M added.
- The largest Eledon Pharmaceuticals seller in Q3 2015 was Tourbillon Capital Partners, an estimated $6.88M sold.
Based on aggregated 13F filings for Q3 2015.